Moderna Inc. and Magenta Investments, a leading pharmaceutical and healthcare company based in the United Arab Emirates (UAE), announced a new agreement to distribute the Moderna COVID-19 Vaccine as well as Moderna’s updated variant booster candidates, once authorized, in the UAE in 2021 and 2022.
“We welcome the opportunity to work alongside Magenta for the distribution of our vaccine in the UAE,” said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. “Together with our partners, we hope to advance our goal to expand access to our vaccine globally, and support governments such as the UAE in protecting their citizens, residents and visitors against the pandemic.”
“As the world continues to endure the drastic impact of the COVID-19 pandemic, we feel privileged to be taking part in the global effort to enhance the protection of humanity by making available this highly advanced vaccine in the United Arab Emirates,” said Dr. Zahid Al Sabti, Managing Director of Magenta Investments.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!